Aligos Therapeutics, Inc. ALGS
5.51
(0.04)
(0.72%)
as of 25 Sep
- Market cap
- $32.6M
- P/E
- 0.0×
Follow ALGS
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 108.53 | 2.89 | 2.93 | 63.27 | 42.14 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (12.62) | (2.39) | (2.01) | (13.56) | (4.24) |
P/B ratio |
— | — | — | — | 2.56 | 0.39 | 0.49 | 0.00 | 1.72 |
Price to Tangible BV |
— | — | — | — | 2.56 | 0.39 | 0.49 | 0.00 | 1.72 |
EV/Sales |
— | — | — | — | 64.80 | (6.15) | (5.80) | 48.84 | 6.54 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.91 | 1.05 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (2.44) | 1.08 | 1.14 | (2.39) | (0.17) |
EV/FCF |
— | — | — | — | (2.42) | 1.07 | 1.14 | (2.38) | (0.17) |
Quick Ratio |
— | 12.20 | 8.55 | 8.06 | 4.90 | 3.80 | 5.68 | 2.62 | 3.67 |
Current Ratio |
— | 12.33 | 8.70 | 8.26 | 5.25 | 4.03 | 5.90 | 2.86 | 3.90 |
Net Debt/EBITDA |
— | 7.66 | 2.24 | 2.59 | 1.53 | 1.34 | 1.59 | 0.63 | 0.87 |
Debt/Assets |
0.00% | 0.02% | 0.12% | 0.05% | 0.11% | 0.16% | 0.15% | 0.17% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | 0.10 | 0.04 | 0.03 |
Operating CF/Net income |
— | 0.43 | 0.89 | 0.68 | 0.90 | 0.83 | 0.90 | 0.62 | 3.41 |
Capex/Depreciation |
— | (1.45) | (1.96) | (0.58) | (0.23) | (0.27) | (0.01) | 0.17 | 0.35 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 35.44% | 132.92% | (139.92%) | (63.41%) | (66.55%) | (89.48%) | (415.84%) | (196.92%) | |
| — | (25.87%) | (41.11%) | (52.71%) | (51.26%) | (50.28%) | (58.80%) | (118.41%) | (30.50%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (15.88%) | (45.48%) | (47.66%) | (74.77%) | (91.27%) | (72.80%) | (306.81%) | (38.10%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 2,389.38% | 611.76% | 470.35% | 1,781.22% | 3,177.17% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 654.44% | 189.90% | 197.15% | 578.71% | 947.76% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 308.72% | 105.65% | 81.47% | 214.25% | 230.74% |
Graham Net Nets |
— | — | — | — | 0.33 | 2.26 | 1.80 | (0.15) | 0.52 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 46.63 | 0.00 |
Earnings Yield |
— | — | — | — | (26.96%) | (240.43%) | (224.20%) | (52.46%) | (14.59%) |
Free Cash Flow Yield |
— | — | — | — | (24.64%) | (200.16%) | (173.88%) | (32.40%) | (90.03%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 2.73 | 8.14 | 6.06 | 0.63 | 0.22 |
Operating CF per Share |
— | (126.81) | (582.40) | (185.89) | (72.55) | (46.49) | (30.82) | (12.89) | (8.35) |
Capex per Share |
— | (52.75) | (34.69) | (5.17) | (0.56) | (0.55) | (0.01) | (0.02) | (0.04) |
Free Cash Flow per Share |
— | (179.56) | (617.10) | (191.06) | (73.11) | (47.04) | (30.83) | (12.91) | (8.39) |
Cash per Share |
— | 1,915.39 | 1,471.99 | 610.95 | 119.75 | 73.75 | 52.97 | 9.11 | 7.89 |
Shareholders Equity per Share |
— | (288.22) | (808.11) | 550.79 | 115.88 | 60.84 | 35.93 | (4.62) | 5.42 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (288.22) | (808.11) | 550.79 | 115.88 | 60.84 | 35.93 | (4.62) | 5.42 |
Free Cash Flow |
— | (8.56) | (49.55) | (76.33) | (116.55) | (80.33) | (79.02) | (80.87) | (82.94) |
Working Capital |
— | 84.88 | 106.41 | 219.74 | 165.47 | 100.42 | 117.18 | 40.40 | 61.63 |
Capital Expenditures |
— | (2.52) | (2.79) | (2.06) | (0.89) | (0.94) | (0.02) | (0.13) | (0.44) |
Net Current Asset Value |
— | (29.11) | (91.18) | 204.75 | 153.79 | 90.75 | 81.64 | (36.93) | 47.87 |
EV/EBIT |
— | — | — | — | 0.00 | 0.88 | 1.02 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.20 | 0.07 | 0.00 | 0.03 | 0.20 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | (2,944.07%) | (690.63%) | (564.61%) | (3,326.01%) | (1,106.72%) |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.60 | 0.17 | 0.44 | 0.63 | 0.73 | 0.81 | (0.32) | (0.67) |
Cash ROIC |
— | (11.50%) | (103.36%) | (17.72%) | (32.41%) | (36.60%) | (36.06%) | (294.72%) | (64.16%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Payables |
— | 3.37 | 3.37 | 3.54 | 3.16 | 3.88 | 3.63 | 2.54 | 3.28 |
Average Assets |
— | 53.87 | 127.13 | 205.91 | 250.34 | 191.03 | 149.11 | 110.81 | 79.31 |
Average Common Equity |
— | (39.32) | (39.32) | 77.57 | 202.39 | 144.32 | 97.99 | 31.55 | 12.29 |
Columns are period end dates